KRAS and malignant colon neoplasm: Indeed, it has been demonstrated that for certain types of mutations, a targeted therapy is feasible (e.g., KRAS G12C inhibitor); hence, the knowledge of which mutations are present inside a colon cancer before surgery could be of paramount importance for the oncologists in order to set up a correct and targeted chemotherapy [29,30].